Instead of focusing on which illnesses are most in need of treatments or cures, too often drug firms base their decisions on money, explains award-winning investigative reporter Billy Kenber, author of ‘Sick Money’
— Read on inews.co.uk/news/health/big-pharma-profits-cancer-rare-diseases-new-drugs-1242812